Molecular Partners AG ADR (MOLN)
Molecular Partners AG ADR is a depositary receipt listed on NASDAQ that represents common stock of Molecular Partners AG, a clinical-stage biotechnology company based in Schlieren, Switzerland. The underlying issuer develops designed ankyrin repeat proteins, or DARPin, therapeutics with a focus on oncology. Its pipeline includes MP0317 for advanced solid tumors, MP053 for acute myeloid leukemia, and MP0712 for small cell lung cancer and neuroendocrine tumors. The company is also advancing additional candidates such as MP0726 and MP0621, while continuing work on its Radio-DARPin Therapy platform for selective delivery of radioactive payloads to solid tumors. Molecular Partners collaborates with Orano Med SAS and Eckert & Ziegler SE on the development of Radio-DARPin therapeutics.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MOLN
|
$3.77
|
-11.4% Downside
|
Fair
|
$10.53
|
147.2% Upside
|
Bargain
|
Fair
|
0.0%
|
October 29, 2026
|
2.2x
|
158.7 M
|
80.881 M
|
2.3%
|
54.1%
|
-6.8
|
90.5%
|
